Abstract. We studied the immunocytochemical localization of urokinase-type plasminogen activator (u-PA) and the type 1 plasminogen activator inhibitor (PAI-1) in human fibroblasts and sarcoma cells, using both polyclonal and monoclonal antibodies. The u-PA was found to be located at discrete cell-substratum contact sites, and also at areas of cell-cell contacts, whereas PAI-1 was distributed as a homogenous carpet excluding strialike areas on the substrate under the cells. To confirm the extracellular localization of u-PA and PAIl, we stained the cells live at 0°C before fixation. A double-labeling experiment showed different distribution of u-PA and PAI-1 under the cells, and especially their peripheral parts. The staining pattern of u-PA and PAI-1 resisted treatment with 0.2% saponin followed by mechanical removal of cells, a method previously reported to isolate focal contact membranes of fibroblasts. We further demonstrated the deposition of u-PA to the contact areas of cells obtained by saponin treatment by zymography, and that of PAI-1 by metabolic labeling, reverse zymography, immunoblotting, and immunoprecipitation. Fibronectin was also present in the preparations. The deposition of both PAI-1 and fibronectin by the sarcoma cells was enhanced, after treating the cells with 10 -6 M dexamethasone. The confinement of u-PA to discrete contact sites and the more uniform distribution of PAI-1 on the cell substratum may explain how cells producing large amounts of enzyme inhibitors can produce PAmediated focal proteolysis.
followed by mechanical removal of cells, a method previously reported to isolate focal contact membranes of fibroblasts. We further demonstrated the deposition of u-PA to the contact areas of cells obtained by saponin treatment by zymography, and that of PAI-1 by metabolic labeling, reverse zymography, immunoblotting, and immunoprecipitation. Fibronectin was also present in the preparations. The deposition of both PAI-1 and fibronectin by the sarcoma cells was enhanced, after treating the cells with 10 -6 M dexamethasone. The confinement of u-PA to discrete contact sites and the more uniform distribution of PAI-1 on the cell substratum may explain how cells producing large amounts of enzyme inhibitors can produce PAmediated focal proteolysis. p LASMINOGErq activators (PAs) ~ are serine proteinases, which by limited proteolysis convert the abundant extracellular proenzyme plasminogen into the active proteinase plasmin. Two different types of PAs have been recognized in mammalian tissues: the urokinase type (u-PA) and the tissue type (t-PA), with approximate Mr 50,000 and 70,000, respectively. Evidence has accumulated indicating that u-PA plays a role in tissue degradation both in the normal organism and in cancer, whereas t-PA is supposed to be a key enzyme in thrombolysis (for reviews see references 12, 13, 16, 46, 58, 59) .
Several of the plasma proteinase inhibitors interact with PAs. Specific protein inhibitors of PA have also been identified in a number of tissues, body fluids, and cell cultures (10, 14, 18, 19, 22, 26, 30, 35, 42, 44, 56, 66, 70, 73, 78, 80, 81, 83) , though the mutual relationship of these inhibitors is not yet fully clarified. An Mr 54,000 plasminogen activator inhibitor (PAI) was recently purified from the human fibrosarcoma cell line HT-1080 (4) , and immunologic evidence sug- : HES, human embryonic skin; PA, plasminogen activator; PAl, PAl-l, or PAl-2, plasminogen activator inhibitor, or specifically, PAl type 1 or type 2; t-PA, tissue-type plasminogen activator; u-PA, urokinase-type plasminogen activator; TNP, trinitrophenyl. gested that it is of the same type as the inhibitors from the rat hepatoma cell line HTC (66) , bovine endothelial cells (18, 42, 44, 56, 70) , and human blood platelets (19) . This inhibitor has been designated plasminogen activator type 1 (PAIl).2 Other types of inhibitors acting on plasminogen activators include the protease nexin I (33, 64, 65) and that present in human placenta (PAI-2) (26, 30, 83) .
Abbreviations used in this paper
Plasmin has a relatively broad specificity, being able to degrade known extracellular matrix glycoproteins and to activate latent collagenase (52, 54, 60) . The affinity of plasminogen and plasminogen activators for laminin (61) , fibronectin (62) , and fibrin (45) further suggests the importance of these proteinases in the turnover of matrix components. Clearly, proteolysis taking place at cellular contact sites is of considerable importance for the interaction between the membrane structures and the surrounding matrix components. Proteolytic targets of the pericellular matrices of cells in culture have been reported to include fibronectin (74) and an Mr 66,000 matrix-associated protein (31) , which seems to be a plasminogen-independent cellular target for u-PA. In addition, a metallo-endoproteinase seems to be involved in the focal degradation of fibronectin substrate by Rous sarcoma virus-transformed chicken and rat cells (11) .
We now report that u-PA is located at cell-substratum and cell-ceU contact sites of cultured human fibroblasts and sarcoma cells, whereas a specific Mr 54,000 PAI is homogeneously distributed on the substrate under the cells.
Materials and Methods

Cell Cultures
The human fibrosarcoma cell line HT-1080 was obtained from the American Type Culture Collection (CCL 121, Rockville, MD). The human embryonic skin fibroblast cultures (2-HES) were established locally by conventional methods and were used at the 10-20 passage level. The ceils were grown either in plastic petri dishes (53 cm 2) or in plastic Linbro wells (2 cm2; How Laboratories, Inc., McLean, VA) in Eagle's minimal essential medium (MEM) supplemented with 10% fetal calf serum (Gibco, Grand Island, NY), 100 IU/ml penicillin, and 50 ~tg/ml streptomycin. Cells were plated onto glass coverslips 24 h before extraction (see below).
Contact Area Preparations
Two procedures for removal of cells were used to prepare samples for immunofluorescence microscopic observations. Method I consisted of washing the cell layers at 0°C three times with PBS (10 mM NaPO4, 145 mM NaCl, pH 7.4). The cultures were then placed in PBS supplemented with 0.2% saponin (white; BDH Chemicals Ltd., Poole, England) and shaken for 20 rain at 0°C on a rotary shaker at 100 rpm. Then the coverslips were intensively pipetted in PBS and the material remaining bound to coverslips was fixed for 20 min in 3 % (wt/vol) paraformaldehyde, prepared in buffered saline. In method H, instead of saponin, the cultures were incubated overnight in cold PBS, thereby letting the ceils detach from the coverslips more slowly. In the morning the cultures were pipetted and washed in PBS and fixed as in method I.
Methods I and II were applied when the proteins remaining associated with the coverslip were to be analyzed. Cells were seeded onto Linbro wells, each well containing one coverslip. After a 24-h incubation at 37°C the medium was changed into serum-free MEM lacking methionine, and the cultures were further incubated for 2 h. The cultures were then metabolically labeled for 2 h with 50 lxCi/ml [35S]methionine (Amersham International, Buckinghamshire, England). The extraction procedure was carried out as detailed above (methods I and 11). After excess buffer had been drained and removed by aspiration, the material remaining attached to the coverslips vats dissolved at 0*C in Laemmli's sample buffer (1.25 M TrisHCt, pH 6.8, containing 4% SDS, 20% glycerol, 0.005% bromphenol blue, and in reduced samples 10% 2-mercaptocthanol). The reduced samples were heated at 100°C for 2 min. Methods I and II gave quantitatively similar results.
Dexamethasone Treatment
Dexamethasone (Sigma Chemical Co., St. Louis, MO) was diluted from ethanol-based stock solution. The final dexamethasone concentration in the culture medium was 10 .-6 M.
Immunofluorescence
Polyclonal purified rabbit IgG and monoclonal (clone 12) mouse antibodies against u-PA, and mouse monoclonal (clone 1) and affinity-purified polyclonal rabbit IgG antibodies against PAl-1 from the HT-1080 cell line were prepared as described elsewhere (4, 34, 49, 50) . Monoclonal antibody against the trinitrophenyl group, anti-TNP-IgG, was from the hybridoma clone designated Hy 2.15 (63) . Rabbit antisera to flbronectin (25) and laminin (1) were produced and their specificity characterized as described. Murine monoclonal antibody fpg-9 to fibronectin was raised and its specificity in solid-phase radioimmunoassay, enzyme immunoassay, and immunoblotting established in collaboration with Drs. S. Barlati, V. Miggiano, and T. Vartio, as described elsewhere for monoclonal antifibronectin antibodies of the same series (76, 77 For immunofluorescent staining, coverslip cultures of cells were washed three times with cold PBS and fixed with either -20°C methanol or 3% (wt/vol) paraformaldehyde for 20 min. The intracellular antigens were exposed by detergent treatment (0.1% Triton X-IO0). The procedures for preparation of cellular contact areas have been detailed above. After additional washes with PBS the coverslips were incubated with the primary antibodies at a concentration of 50 I~g/ml (antibodies to u-PA and the Mr 54,000 inhibitor) or diluted 1:100 (rabbit antifibronectin, rabbit antilaminin, and antivinculin sera) or 1:30 (monoclonal fpg-9 antifibronectin ascites) for 30 min. This was followed by a short rinse in PBS and incubation with fluorochrome (FITC/TRITC)-conjugated anti-rabbit/mouse immunoglobulins 
Immunoelectron Microscopy
The Linbro wells with cells were briefly rinsed three times with Dulbecco's PBS (DPBS) containing 0.2% BSA at 0°C, and then incubated with the primary antibody for 30 min, the entire experiment being made at 0°C. After rinsing three times with DPBS + 0.2% BSA, the cells were fixed with 1% glutaraldebyde (Sigma Chemical Co.) in 0.1 M phosphate buffer, pH 7.2, for 20 min, followed by treatment with 5 mg/ml NaBI-h in the same phosphate buffer for 30 min. The cells were washed then three times with DPBS + 0.2% BSA, and then incubated with Perox Aflini pure goat anti-rabbit IgG (H&L, Jackson Immuno Research Laboratories Inc., Avondale, PA) o diluted 1:30 in DPBS + 0.2 % BSA at 0 C for 30 min, and washed thereafter five more times. The peroxidase-catalyzed staining reaction was performed with the following mixture: 0.05 % diaminobenzidine (Sigma Chemical Co.) and 0.001% H202 in 0.05 M Tris-HCl buffer, pH 7.6. After a 10-min staining, the cells were briefly rinsed three times with PBS, and postfixed with 1.5% OsO4 in 0.1 M cacodylate buffer, pH 7.2, for 1 h at room temperature, and dehydrated with ethanol. The wells were mounted in Epon 812. After polymerization for 2 d, the Epon blocks were sectioned vertically against the cell layer. Thin sections (about 80 nm) were observed in a Jeol 100 CX TEMSCAN electron microscope at 40.0 kV at the Department of Electron Microscopy, University of Helsinki, Finland.
Polyacrylamide Gel Electrophoresis (PAGE) and Immunoblotting
Preparation and electrophoresis of samples in 8 % and 5-16 % gradient SDS polyacrylamide slab gels were as described by Laemmli (36) . pore Corp., Bedford, MA) was performed using immunoperoxidase staining according to Towbin et al. (72) as modified (75) . Commercially available low molecular weight markers (Pharmacia Uppsala, Sweden) and ~C-labeled markers (Amersham International) were used.
Zymography
The contact area preparations were analyzed for PA activity as described previously (23) . Briefly, after electrophoresis in an 8 % polyacrylamide slab gel under nonreducing conditions and without heating the specimen, SDS was removed from the gels with extensive washing on a gyratory shaker for 6 h in PBS with 2.5 % Triton X-100, and an indicator agarose gel containing casein and plasminogen was placed in contact with the polyacrylamide gel. An agarose gel lacking plasminogen was used as a control. To determine the type of the PA activity, contact area preparations were dissolved in 0.5 % Tri~n-X-100 and run through a column of Sepharose-coupled monoclonal anti-u-PA or anti-t-PA before running the specimens in SDS PAGE. PAIs in polyacrylamide gels were detected by washing the gel first in the same solution as above, but containing 50 IU of u-PA in 100 mi of washing solution (Calbiochem Behring Corp., La Julia, CA). When layered over an agarose gel containing casein and plasminogen, a general lysis of the casein took place except where inhibitors were present in the polyacrylamide gels. These positions were revealed by opaque lysis-resistant zones: reverse zymography (20) .
u-PA and PAI-1 Preparations
u-PA was from a commercial preparation (Mr 54,000, 60,000 IU/mg, Calbiochem). PAI-1 was purified from conditioned culture medium of dexamethasone-treated HT-1080 cells as described in detail elsewhere (4) . Iodination of u-PA and PAI-1 was carded out with the Iodo-Gen method (Pierce Chemical Co., Rockford, IL).
Immunoprecipitation
For the immunoprecipitation experiment, metabolically labeled cells were extracted using method I (see above), the contact area material being dissolved in 500 Ixl of 0.1% (wt/vol) SDS, 0.5% (vol/vol) Triton X-U4, 50 mM Tris-HCI buffer, pH 8.0, 150 mM NaC1. 70 ~tl of 10% (wt/vol) solution of washed Protein A-Sepharose CL-4D beads (Pharmacia) in 50 mM Tris-HCl buffer, pH 8.0, 150 mM NaCI was added, and after 15 min beads were separated by centrifugation at 9,000 g for 1 min. 5 lxl of the monoclonal antibody against PAI-I was added to the supernatant, and the mixture was incubated overnight at 4°C. The samples were further incubated with Protein A-Sepharose beads as above for 60 min at 37"C in an end-over mixer. The precipitate was washed four times with the dissolving buffer and once with 50 mM Tris-HC1, pH 8.0, 150 mM NaCI, before resolvement by SDS PAGE on 8 % acrylamide gels. The dried gels were exposed on to Kodak XAR-5 film for autoradiography.
Conversion of AddedU~I-u-PA to a High Molecular Mass Form in Contact Area Preparations
~2SI-u-PA prepared as described above and diluted in PBS (106 cpm/ml), was added to freshly prepared contact area material of 2-HES fibroblasts obtained by saponin treatment as described. After incubation for 60 min at 4°C the preparations were washed with PBS, and the bound proteins were dissolved in Laemmli's sample buffer under nonreducing conditions, and analyzed in SDS PAGE followed by autoradiography.
Results
lmmunocytochemical Localization of u-PA and PAI-1
HT-1080 and 2-HES cells were grown on glass coverslips overnight. After rinsing with ice-cold PBS, the cells were fixed or removed either by treating them with 0.2% saponin or by letting them shed overnight in PBS at 4°C as described in Materials and Methods. The fixed cells and the material remaining on the coverslips were examined by immunofluorescence microscopy. Using both a polyclonal and a monoclonal antibody we found u-PA to be located at cell substratum contact sites of HT-1080 fibrosarcoma cells. Staining was also detectable in areas of cell-cell contacts (Fig. 1, A and C) . The label associated with the substratum resisted the saponin extraction procedure, making the footprint contact pattern of immunofluorescence even more evident (Fig. 1, B and D) . When live HT-1080 cells were stained, we detected patches of staining at cell-cell contacts and a weak diffuse pattern of immunofluorescence over the dorsal surfaces of cells (see Fig. 4 A) , in addition to that in the contact sites on the substratum (see Fig. 4 B) . These results demonstrate the extracellular location of the u-PA antigen. Intracellular anti-u-PA staining was also seen, showing highest intensity in the perinuclear region (Fig. 1, A and C) . This was particularly the case, when cells were fixed with paraformaldehyde followed by various permeabilization procedures (not shown). At the electron microscopic level we could observe patches of polyclonal antiu-PA staining extracellularly in association with the plasma membrane. Occasionally, a patch of stain formed a contact between two neighboring HT-1080 cells (Fig. 2 A) . Human fibroblasts showed much lower staining intensity for u-PA than sarcoma cells. Only rarely were we able to detect a contact site staining pattern similar to that visualized in Fig. 1 E.
Staining with a monoclonal antibody to PAI-1 gave a similar pattern in fibrosarcoma cells and in fibroblasts. The immunofluorescence consisted of a homogeneously layer on the substratum. There was also intracellular perinuclear staining with very intensive labeling, presumably indicating PAl-1 synthesis (Fig. 3, A and B) . After saponin extraction of cells, the immunofluorescence consisted of a homogenous carpet in the cell peripheral area interrupted by striae of negative staining ( Fig. 3 C and D) , which were also very faintly present in cells fixed with -20°C methanol (see Fig. 5 A) . Affinity-purified polyclonal rabbit anti-PAi-I IgG gave similar staining patterns as the monoclonal antibody. In cells stained live at 0°C with anti-PAI-1 antibodies, the immunofluorescence was restricted to the peripheral parts of the cells whereas the central areas appeared negative (Fig. 4 C) . We interpret this to be the result of antigen in accessibility on the substrate under live cells in that the antigen was seen in the saponin-treated preparation on the substratum (Fig. 3, C and  D) . Double-stained HT-1080 cells, featured in Fig. 5, A and B, show that u-PA and PAI-1 have distinct staining patterns especially on the peripheral parts of the cells.
Fibronectin was detected with a polyclonal and the fpg-9 monoclonal antibody in both cell lines. The saponin contact preparations of fibroblasts displayed a typical matrix pattern, whereas in HT-1080 preparations the corresponding pattern was dominated by dots and striae. Fig. 1 G shows the fpg-9 staining pattern in a contact area preparation of dexamethasone treated HT-1080 cells. Neither HT-1080 nor fibroblast contact preparations displayed vinculin or laminin, as investigated by immunofluorescence using polyclonal antibodies.
Specificity controls including the use of up to 50 ~tg/ml preimmune IgG corresponding to the anti-u-PA or anti-PAIl and monoclonal anti-TNP-IgG were negative, as were experiments in which one of the steps in the staining protocol was omitted (Fig. 2 B) . Absorption of the antibodies with either highly purified u-PA (Fig. 1 F) or PAl-1 (not shown) completely abolished the staining described above.
psS]Methionine Labeling and Immunoprecipitation
To characterize the macromolecular components of the con- The material attached to the glass coverslip was analyzed in SDS-PAGE followed by autoradiography. One major band run at Mr 54,000 and coelectrophoresed with purified radiolabeled PAI-1 (Fig. 6 , lane 5) in HT-1080 as well as fibroblast contact preparations. The monoclonal anti-PAI-1 antibody also immunoprecipitated a similar band from the preparation (see Fig. 10 ). However, the precipitation of PAI-1 did not resuit in a quantitative depletion of the Mr 54,000 band from the immune supernatant. Thus, it cannot be excluded that there are at least two Mr 54,000 proteins comigrating in the metabolically labeled contact area preparation. Enriched in the contact area preparations were also bands at Mr 60,000, 75,000, and 250,000. Dexamethasone in the culture medium increased the intensity of the Mr 54,000 and 250,000 bands on the HT-1080 contact preparations (Fig. 6, lanes 1-2 and  8-9 ), as expected of the PAI-1 (2, 4, 14, 66) and fibronectin subunits (53) . The Mr 54,000 band also appeared increased in the contact area preparations from dexamethasone-treated fibroblasts with SDS-PAGE under reducing conditions, but not with SDS PAGE under nonreducing conditions. This apparent discrepancy is due to the fact that less total protein was undeliberately applied to the gel lane corresponding to fibroblasts without dexamethasone electrophoresed under reducing conditions,
Zymographic and Reverse Zymographic Analysis of the Contact Area Preparations
Molecular forms of the plasminogen activators present in the contact area preparations were investigated by SDS-PAGE under nonreduced conditions followed by casein-agarose zymography (Fig. 7) . In the contact area preparations of liT-1080 cells (lanes 1 and 2) , PA activity migrated as a welldefined band at Mr 50,000, as expected of u-PA. Additionally, higher molecular mass forms of PAs were detected as a smear of activity between Mr 70,000 and 100,000, with a distinctive band at the latter end. Dexamethasone slightly diminished the PA activity in the preparations. All the PA activity in the preparations is u-PA, in that preparations run through a column of Sepharose coupled monoclonal antiu-PA antibodies lost all their PA activity, while treatment in a similar anti-t-PA column had no effect on the PA activity pattern of the preparations (data not shown). This indicates that PAI-1 and u-PA form a complex in the preparation which dissociates partly during electrophoresis, in agreement with previous fndings (4) . The reason that the lysis zone is not continuous between positions corresponding to Mr 50,000 and 100,000 can be ascribed to the fact that excess inhibitor migrates slightly behind uncomplexed u-PA, preventing lysis in that position. Virtually no PA activity was detected in fibroblast contact preparations using this method (lanes 3 and 4); only after several days' exposure did a weak lysis appear at Mr 50,000. Control gels lacking plasminogen showed no caseinolytic activity.
Reverse casein agarose zymography was carried out to test for PA inhibiting activities (Fig. 8) . Analysis of the contact area preparations of HT-1080 cells as well as fibroblasts revealed a major inhibitor zone at Mr 54,000. Dexamethasone markedly increased the intensity of the inhibitor zone of the HT-1080 contact area preparations (lanes 1 and 2), but this effect was virtually non-existent in the fibroblast preparations (lanes 3 and 4) .
Immunoblotting
Contact area preparations of dexamethasone-treated HT-1080 cells were subjected to immunoblotting analysis under reducing conditions. The monoclonal PAI-1 antibody detected a single band at M~ 54,000 (Fig. 9, lane 1) . Lane 2 is a specificity control track immunoblotted with anti-TNP-IgG. 
Complexing of uSI-u-PA in Contact Area Preparations of tqbroblasts
When uSI-u-PA (Mr 50,000, Fig. 11 , lane a) was added to preparations obtained from cultures of 2-HES fibroblasts using method I, and incubated for 60 min in the cold, a large proportion of the bound label was converted to a high molecular mass form: Mr 90,000 (Fig. 11, lane b) . A similar high molecular mass complex was obtained after incubation of t25I-u-PA with excess amounts of PAI-1 purified from the HT-1080 cell line (lane c).
Discussion
In the present study we have described the distribution of u-PA and an Mr 54,000 PAI in cultured HT-1080 human fibrosarcoma cells and in human fibroblasts using both polyclonal and specific monoclonal antibodies. In our experiments, u-PA was found to be located at discrete cellular contact sites under the fibrosarcoma cells, whereas its inhibitor was distributed as a homogeneously thick carpet on the sub- Figure 6 . Macromolecular components of the contact area preparations. Metabolically labeled cells were extracted using the saponin procedure (method I), and the material remaining attached to the glass coverslips was dissolved in Laemmli's sample buffer, 500 ~tl per coverslip. 70 I11 aliquots of the samples were analyzed by 5-16% polyacrylamide gradient SDS PAGE under reducing (lanes 1-4) and nonreducing (lanes 5-9) conditions, followed by autoradiography. The contact area preparations of dexamethasone-treated (lanes 1 and 9) and untreated (lanes 2 and 8) HT-1080 cells, and dexamethasone-treated (lanes 3 and 7) and untreated (lanes 4 and 6) 2-HES cells. Lane 5: purified radiolabeled PAI-1. The molecular mass of the marker proteins (reduced) is shown in kilodaltons. stratum, but lacking in strialike areas. When live cells were stained, PAl-1 could not be detected under the central parts of the cells. Thus, we cannot exclude the possibilty that the negative strialike areas in saponin-treated cell preparations would be due to inaccessibility of the PAl-1 antigen to the antibodies used. At the electron microscopic level we detected patches of anti-u-PA staining associated with the plasma membrane. This result, obtained by staining live cells in the cold with the primary antibody, indicated that u-PA on the cell surface is externally located. The deposition of fibronectin was also detected using a monoclonal antibody. Normal human fibroblasts showed low intensity of anti-u-PA immunoreactivity, while producing PA inhibitor quite abundantly.
Additional lines of evidence were obtained, suggesting that u-PA and its inhibitor are indeed deposited to the contact areas of cells. First, the contact areas could be isolated with 0.2 % saponin assisted mechanically with a stream of buffer. When such cell-free substrate-attached material, prepared from [35S]methionine-labeled cells, was studied by fluorography, we found that an Mr 54,000 band was the major one in the preparations. This band includes PAl-l, as judged by immunoprecipitation experiments, although the presence of other proteins in the same position cannot be excluded. Still, its amount in the preparations was responsive to dexamethasone treatment of the HT-1080 cell cultures in agreement with the previous findings (2, 4, 14, 53, 66) . PAl-1 in the contact area preparations could be immunoblotted with a specific monoclonal antibody. Apparently, u-PA is a relatively minor component in the contact area preparations; we were unable to detect u-PA in these preparations using immunoblotting. The PA activity of the contact area preparations was, however, confirmed with zymography which showed a major band at Mr 50,000 as well as a minor band at Mr 100,000. Reverse zymography showed a single Mr 54,000 inhibitor in the preparations. Furthermore, when 125I-u-PA was incubated with the preparations, much of it was converted into a high molecular mass form (Mr 90,000). This observation is consistent with the presence of PAI-1 in con- tact area preparations, but further experiments are needed to determine whether the complexing of ~SI-u-PA is specifically with PAId.
The accessibility of u-PA for antibodies at the contact sites differed under various fixation and permeabilization conditions, methanol fixation at -20°C giving the clearest results. Even then, the monoclonal antibodies gave much less staining than the polyclonal anti-u-PA antibodies we used. After removal of cells to obtain the contact area preparations both types of antibodies gave a similar pattern of staining, suggesting that the determinant of the monoclonal antibody is restrictedly exposed.
The subcellular localization of u-PA has been previously explored by cell fractionation studies and by the immunocytochemical approach. Despite conflicting results, there appears to be a consensus among the various cell fractionation reports that PA activity is often localized in membrane-rich fractions. In Rous sarcoma virus-transformed chicken embryonal fibroblasts, u-PA has been localized to fractions containing the Golgi apparatus and the plasma membrane (57), whereas in growing and virus-transformed 3T3 cells exclusively to the plasma membrane-enriched fraction (28, 29) . However, in a study of HT-1080 cells PA of non-determined type was found associated solely with a cellular fraction representing either the Golgi apparatus or secretory granules rather than plasma membrane (39) . Interestingly, either u-PA or PA of nondetermined type from several cell lines includ- ing HT-1080, has been found resistant to various solubilization procedures that would be expected to solubilize nonmembrane integrated proteins (28, 39, 41, 43, 57, 69) . As for the light microscopic studies the subcellular distribution of u-PA differs greatly in different cell types (38, 67) . Only one study at the electron microscopic level PA (apparently u-PA) immunoreactivity has been reported to be associated with the cell membranes of porcine kidney cells (55) . Furthermore, in two recent studies of human monocyte-like U937 cells and peripheral blood monocytes (71, 79), u-PA was shown to bind with its noncatalytic aminoterminal domain to specific plasma membrane receptors, whereas the catalytic, carboxyterminal domain remains exposed on the cell surface. Additionally, Fibbi et al. (21) have demonstrated the binding of a urokinase-ferritin conjugate to cell surface sites in A431 human epidermoid carinoma cells and proposed that these represented single and clustered receptor. Our data fit well with the findings above. If indeed u-PA is bound to a receptor also in HT-1080 cells, the anti-u-PA immunoreactivity at the contact sites and on the plasma membrane (Fig. 2 A) could be based on local clustering of such receptors.
Several different procedures have been used to isolate material designated either as cellular contact sites, cell substratum-attached material, foot pads, or focal contact membranes (5, 7, 9, 15, 37, 40, 47) . These procedures include use of chelating agents, low concentrations of nonionic or zwitterionic detergents, or mechanical extraction. All these procedures to isolate the material from the growth substratum should be considered operational only, because the material obtained is expected to conulin both extracellular matrix components and material binding from the culture medium to the glass or plastic surface, besides the actual cellular contact site components. Saponin, which we used as a cholesterol-removing detergent, has also been used to isolate acethylcholine receptor clusters from cultured rat myotubes (8) . In addition, using saponin and mechanical extraction Neyfakh et al. (47) found Mr 51,000 and 47,000 proteins in isolated focal contact membranes of mouse and chick fibroblasts, respectively. Interestingly, Bayley and Rees (7) detected a major new protein component with an Mr 50,000-55,000 in fibroblast focal adhesion preparations that remains attached to a glass substratum after cells are mechanically removed. Our results indicated that a contact area preparation obtained by saponin treatment contains PAId. However, the inhibitor was not confned to discrete focal contacts, nor was it found to have a matrix-type distribution, instead it was found to be deposited under the ventral surface of the cells excluding strialike areas.
Extracellular PA activity may be regulated at the level of cellular production and release of the activators themselves, and by modulators of the enzyme activity of the activators (for reviews, see references 16 and 59). Furthermore, the fact that PAs act as a part of a cascade reaction implies a more complicated set of control mecahnisms for the final proteolytic effect. Recent demonstration of proenyzmes with little or no activity (3, 17, 27, 32, 51, 67, 68, 82) suggests that mechanisms, although at present unknown, exist that control the conversion of zymogens to active enzymes in the extracellular space. Moreover, u-PA is inhibited by the abundant protease inhibitors of the human plasma, by the protease nexin, and by the recently reported more specific inhibitors (see our introductory text for references). Binding by pro-tease nexin may initiate cellullar uptake and degradation of u-PA.
Our results demonstrating u-PA and PAI-1 in the contact area preparations add a novel dimension to the complex regulatory scenario of pericellular plasminogen activation. The protein concentration being too low in our preparations, we were not able to decide by immunoblotting, whether u-PA at the sarcoma cell contact sites is present as the one-chain inactive proenzyme. The results obtained by zymography, demonstrating a PAI-1/u-PA complex that is not formed by pro-u-PA (4), do not settle that question because pro-u-PA may have been activated during the zymography procedure. The difference in distribution between u-PA, being enriched into discrete contact sites, and PAI-1, being distributed as an extracellular carpet on the growth substratum, could conceivably permit focal u-PA-mediated proteolysis to occur.
The large amounts of the PAI on the growth substratum was a rather unexpected finding. This could be an indication of the need to secure the inhibition of PA in the pericellular area, to maintain cell surface integrity. Proteins bound in a similar way on to glass substrata include serum spreading factor (vitronectin), and the Mr 80,000 protein of serumcontaining media (48). Vitronectin is an adhesive glycoprotein that promotes spreading of a variety of cell types on culture dishes (6, 24). The deposition of PAI-1 suggests that it may have functions other than enzyme inhibition. We are currently exploring this possibility.
